Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 16 CNS 11 Sarcoma 3 Head & Neck 2 Gastrointestinal 2 Dermatologic 2 Thoracic 1 Lymphoid 1 Breast 1

Conditions

Estrogen Receptor Positive Breast Cancer 1

Interventions

Trastuzumab 728 Paclitaxel 694 Cyclophosphamide 647 Docetaxel 559 Capecitabine 485 Letrozole 437 Fulvestrant 398 Carboplatin 397 Doxorubicin 341 Tamoxifen 308 Anastrozole 279 pembrolizumab 272 exemestane 258 Epirubicin 251 Radiotherapy 239 pertuzumab 237 palbociclib 224 Bevacizumab 222 Gemcitabine 215 Vinorelbine 197 Lapatinib 181 130-nm albumin-bound paclitaxel 172 Magnetic Resonance Spectroscopy 164 Albumin-Bound Paclitaxel 157 eribulin 154 Surveys and Questionnaires 151 Exercise 151 Drug Therapy 141 Taxes 134 Fluorouracil 133

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Transurethral Resection of Bladder × Breast × Clear all

NCT06629233 2025-08-29

Tn-Miner

University Ghent

Phase NA Enrolling by invitation

Estrogen Receptor Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡